Select year

2026 2025 2024 2023 2022 Earlier

shown/page

10

2025.12.07

Chidamide is Included in the National Reimbursement Drug List (NRDL) as a Regular Category B Drug
Chidamide is Included in the National Reimbursement Drug List (NRDL) as a Regular Category B Drug

2025.12.05

Dr. Lu Xianping of Chipscreen Biosciences Wins the 2025 EY Entrepreneur Of The Year - Mainland China Award
Dr. Lu Xianping of Chipscreen Biosciences Wins the 2025 EY Entrepreneur Of The Year - Mainland China Award

2025.11.19

Chipscreen Biosciences Joins Hands with StoneWise to Co-build a Novel End-to-End AI-Powered Paradigm for Early-Stage Drug Discovery
Chipscreen Biosciences Joins Hands with StoneWise to Co-build a Novel End-to-End AI-Powered Paradigm for Early-Stage Drug Discovery

2025.11.15

Chipscreen Biosciences Showcases Source Innovation Achievements Including CS231295 at the 27th CHTF
Chipscreen Biosciences Showcases Source Innovation Achievements Including CS231295 at the 27th CHTF

2025.11.03

ESMO 2025 | Chidamide Combined with PD-1 Antibody Sets New Record in Treating Advanced Sarcoma: ORR 30.4%, DCR 73.9%
ESMO 2025 | Chidamide Combined with PD-1 Antibody Sets New Record in Treating Advanced Sarcoma: ORR 30.4%, DCR 73.9%

2025.10.15

ESMO 2025 | Study Results on Chidamide's HDACi+IO Strategy Selected for Proffered Paper Session
ESMO 2025 | Study Results on Chidamide's HDACi+IO Strategy Selected for Proffered Paper Session

2025.09.25

Leading with Source Innovation: Chipscreen Biosciences and Chiglitazar Sodium (Bilessglu®) Honored with A Decade of Glory for China's Innovative Drugs Awards
Leading with Source Innovation: Chipscreen Biosciences and Chiglitazar Sodium (Bilessglu®) Honored with A Decade of Glory for China's Innovative Drugs Awards

2025.08.18

Chipscreen Biosciences 2025 Innovation Summit Concludes Successfully: AI + Integrated Core Technology Platform Fuels Original New Drug Development
Chipscreen Biosciences 2025 Innovation Summit Concludes Successfully: AI + Integrated Core Technology Platform Fuels Original New Drug Development

2025.08.07

International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment
International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment

2025.07.31

Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development
Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

01
02

Media contact

Media contact

（+86）0755-36993500
pr@chipscreen.com